Lilly 4Q Revenues: $6.0 billion (-2%) 4Q Earnings: $858.2 million (-27%) FY Revenues: $24 billion (+5%) FY Earnings: $4.3 billion (-14%) Comments: U.S. revenue was down 4% to $3.3 billion due to the loss of patent exclusivity for Zyprexa and Gemzar. Revenue outside the U.S. remained flat at $2.8 billion due to increased volume and the positive impact of foreign exchange rates, offset by lower prices. For the year revenue in the U.S. was $13.0 billion (+1%). Revenue outside the U.S. increase...